Targeted Therapies for Cancer: ImmunoGen, Inc.

Site Map

ImmunoGen, Inc. develops targeted anticancer therapeutics. Our proprietary Targeted Antibody Payload (TAP) technology and strong antibody expertise form the basis for our development of our own products as well as of our partnerships with other companies.

Multiple compounds are in the clinic through our own programs and those of our partners.

Learn more about them...

ImmunoGen’s Targeted Antibody Payload (TAP) technology can expand the potential of monoclonal, or manufactured, antibodies in the treatment of cancer.

Learn more about some of our linker innovations...

6/23/2009
ImmunoGen, Inc. Announces Completion of Public Offering of Common Stock

6/22/2009
ImmunoGen, Inc. Announces Exercise of Over-allotment Option

Read our releases...

built@zoomedia.com

Last updated June 23, 2009